The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Acquired Immunodeficiency Syndrome (AIDS) Market Be By 2030 Compared To Its 2026 Market Size?
The market size for acquired immunodeficiency syndrome (aids) has shown substantial growth in recent years. It is forecast to expand from $33.75 billion in 2025 to $35.53 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.3%. Historically, this growth can be attributed to the significant worldwide prevalence of HIV infections, expanding awareness and screening initiatives, government-supported HIV treatment programs, the availability of first-generation antiretroviral drugs, and an escalating incidence of opportunistic infections.
The market size for acquired immunodeficiency syndrome (aids) is projected to undergo substantial expansion in the next few years. It is anticipated to reach $43.28 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 5.1%. This growth throughout the forecast period can be primarily attributed to the ongoing development of next-generation antiretroviral therapies, the expansion of PrEP and PEP programs, heightened research efforts for HIV vaccines, the increasing adoption of digital health monitoring solutions, and a rise in public-private partnerships aimed at HIV management. Significant trends expected during this forecast period encompass the increasing uptake of antiretroviral therapy (ART), a growing reliance on pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP), the broadening of HIV diagnostic and surveillance programs, an intensified focus on HIV vaccine research and development, and the integration of services provided by hospital and retail pharmacies.
Access Your Free Sample Report For In-Depth Market Analysis:
What Key Factors Are Shaping The Acquired Immunodeficiency Syndrome (AIDS) Market Landscape?
Rising instances of HIV infections are anticipated to boost the expansion of the acquired immunodeficiency syndrome (AIDS) market in the future. HIV infections describe a state triggered by the human immunodeficiency virus (HIV), which compromises the immune system, thereby diminishing the body’s capacity to combat infections and illnesses. The surge in HIV infection rates stems from factors such as unprotected sexual contact with an infected individual, the shared use of needles or syringes, exposure to tainted blood products, engaging with multiple sexual partners, and having a compromised immune system or pre-existing sexually transmitted infections. Management of acquired immunodeficiency syndrome (AIDS) supports patients with HIV infection by encouraging prompt diagnosis, broadening availability of potent antiretroviral treatments, improving prevention tactics, and reinforcing healthcare infrastructure, all of which aid in better managing the virus’s dissemination. As an illustration, data released in November 2024 by the European Centre for Disease Prevention and Control (ECDC), a Sweden-based European Union agency, indicated that 112,883 HIV diagnoses were documented in 2023 across 47 out of 53 regional countries, including 24,731 cases within the European Union/European Economic Area (EU/EEA). The total crude rate for HIV diagnoses reached 12.7 per 100,000 population, representing a 2.4% rise from the 12.4 per 100,000 rate noted in 2022. Consequently, the rising number of HIV infections is propelling the acquired immunodeficiency syndrome (AIDS) market.
Which Segment Categories Are Included In The Acquired Immunodeficiency Syndrome (AIDS) Market Segment Analysis?
The acquired immunodeficiency syndrome (aids) market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1, Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Anatagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral, Parenteral
4) By Application: Hospital Pharmacy, Retail Pharmacy, Other Applications
5) By Distribution Channel: Offline, Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), HIV-1 Diagnostic Tests, HIV-1 Vaccine Development, HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2, HIV-2 Diagnostic Tests, HIV-2 Surveillance And Epidemiology, HIV-2 Vaccine Research, Management Of HIV-2 Co-Infections
What Market Trends Are Affecting The Acquired Immunodeficiency Syndrome (AIDS) Market?
Major companies engaged in the acquired immunodeficiency syndrome (AIDS) market are concentrating on creating novel therapies, such as long-acting injectables, which enhance patient adherence, decrease dosing frequency, and offer a more practical option than daily oral antiretroviral medications. Long-acting injectables are medications given by injection, designed to gradually release their active components over an extended period, allowing for less frequent administration compared to traditional oral drugs. As an illustration, in January 2025, the UK-based pharmaceutical company, GSK plc, declared that the European Commission had granted approval for its long-acting injectable treatment, Vocabria (cabotegravir) plus Rekambys (rilpivirine). This treatment is sanctioned for use in adolescents aged 12 years and older who are living with HIV, administered via intramuscular injection typically every one or two months, based on the specific treatment regimen. The extended duration of these injections has the potential to boost adherence among adolescents who find daily pill regimens challenging.
Who Are The Active Companies Shaping The Acquired Immunodeficiency Syndrome (AIDS) Market?
Major companies operating in the acquired immunodeficiency syndrome (aids) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy’s Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare
Get The Full Acquired Immunodeficiency Syndrome (AIDS) Market Report:
Which Geographic Region Dominates The Acquired Immunodeficiency Syndrome (AIDS) Market?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (aids) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Acquired Immunodeficiency Syndrome (AIDS) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Acquired Immunodeficiency Syndrome (AIDS) Market 2026, By The Business Research Company
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Acne Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report
Walking Aids Market Report 2026
https://www.thebusinessresearchcompany.com/report/walking-aids-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model